Floatz logo

Trientine

Ovarian Neoplasms Malignant (Excl Germ Cell)

National Cheng-Kung University HospitalSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Ovarian Neoplasms Malignant (Excl Germ Cell) cohort.

Asset / SponsorPhaseRating
Carboplatin
Wake Forest University Health Sciences
Phase 2BB
Niraparib
CanariaBio Inc.
Phase 2CCC
Inno-206
National Cheng-Kung University Hospital
Phase 1/2CCC
Avelumab
University of Texas Southwestern Medical Center
Phase 2CCC
IMMUNOGLOBULIN G1, ANTI-(HUMAN CA125 (CARBOHYDRATE ANTIGEN)) (MOUSE MONOCLONAL B43.13.GAMMA.1-CHAIN), DISULPHIDE WITH MOUSE MONOCLONAL B43.13.KAPPA.-CHAIN, DIMER
CanariaBio Inc.
Phase 2CC
Dordaviprone
Ira Winer
Phase 2CC

Same molecule, other indications

Trientine is also rated in:

Wilson diseaseDormant
BB
Indicative ·
71 / 100
View asset →
peritoneal carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
fallopian tube cancerDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →